Pfizer-BioNTech's COVID Vaccine Gets Approval in South Korea for Kids 5-11 - Reuters

Seeking Alpha2022-02-23

South Korea approved Pfizer (NYSE:PFE) BioNTech's (NASDAQ:BNTX) coronavirus vaccine for use in children ages five to 11 years, Reuters reported citing the Asian country's food and drug ministry.
The kids will receive 1/3 the regular dose. The vaccine would be given twice with a three week gap.
Children who have significant declined immunity would be eligible for a booster shot after four weeks, said the report.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

tobe.....
2022-02-23
tobe.....
Big player alway knowing their ways and get supported[LOL]

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2213967923?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-23 17:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2213967923","market":"us","top_or_hot":-1,"title":"Pfizer-BioNTech's COVID Vaccine Gets Approval in South Korea for Kids 5-11 - Reuters","media":"Seeking Alpha","content":"<html><head></head><body><ul><li>South Korea approved Pfizer (NYSE:PFE) BioNTech&#39;s (NASDAQ:BNTX) coronavirus vaccine for use in children ages five to 11 years, Reuters reported citing the Asian country&#39;s food and drug ministry.</li><li>The kids will receive 1/3 the regular dose. The vaccine would be given twice with a three week gap.</li><li>Children who have significant declined immunity would be eligible for a booster shot after four weeks, said the report.</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer-BioNTech's COVID Vaccine Gets Approval in South Korea for Kids 5-11 - Reuters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer-BioNTech's COVID Vaccine Gets Approval in South Korea for Kids 5-11 - Reuters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-23 17:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3803082-pfizer-biontechs-covid-vaccine-gets-approval-in-south-korea-for-kids-5-11-reuters><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>South Korea approved Pfizer (NYSE:PFE) BioNTech's (NASDAQ:BNTX) coronavirus vaccine for use in children ages five to 11 years, Reuters reported citing the Asian country's food and drug ministry.The ...</p>\n\n<a href=\"https://seekingalpha.com/news/3803082-pfizer-biontechs-covid-vaccine-gets-approval-in-south-korea-for-kids-5-11-reuters\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4534","symbol_name":"瑞士信贷持仓","start_time":0,"source_url":"https://seekingalpha.com/news/3803082-pfizer-biontechs-covid-vaccine-gets-approval-in-south-korea-for-kids-5-11-reuters","article_id":"2213967923","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2213967923","pubTimestamp":1645609479,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"South Korea approved Pfizer (NYSE:PFE) BioNTech's (NASDAQ:BNTX) coronavirus vaccine for use in child","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","PFE":"辉瑞","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓"},"translate_title":"辉瑞-生物技术公司的COVID疫苗在韩国获得批准，适用于5-11岁的儿童-路透社","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"South Korea approved Pfizer (NYSE:PFE) BioNTech's (NASDAQ:BNTX) coronavirus vaccine for use in children ages five to 11 years, Reuters reported citing the Asian country's food and drug ministry.The kids will receive 1/3 the regular dose. The vaccine would be given twice with a three week gap.Children who have significant declined immunity would be eligible for a booster shot after four weeks, said the report.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":9030964463,"gmtCreate":1645611041919,"gmtModify":1676534045176,"author":{"id":"4095370255462710","authorId":"4095370255462710","name":"tobe.....","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4095370255462710","idStr":"4095370255462710"},"htmlText":"Big player alway knowing their ways and&nbsp;get supported[LOL]&nbsp;","listText":"Big player alway knowing their ways and&nbsp;get supported[LOL]&nbsp;","text":"Big player alway knowing their ways and get supported[LOL]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030964463","repostId":2213967923,"repostType":4,"repost":{"id":"2213967923","kind":"news","pubTimestamp":1645609479,"share":"https://ttm.financial/m/news/2213967923?lang=en_US&edition=fundamental","pubTime":"2022-02-23 17:44","market":"us","language":"en","title":"Pfizer-BioNTech's COVID Vaccine Gets Approval in South Korea for Kids 5-11 - Reuters","url":"https://stock-news.laohu8.com/highlight/detail?id=2213967923","media":"Seeking Alpha","summary":"South Korea approved Pfizer (NYSE:PFE) BioNTech's (NASDAQ:BNTX) coronavirus vaccine for use in child","content":"<html><head></head><body><ul><li>South Korea approved Pfizer (NYSE:PFE) BioNTech&#39;s (NASDAQ:BNTX) coronavirus vaccine for use in children ages five to 11 years, Reuters reported citing the Asian country&#39;s food and drug ministry.</li><li>The kids will receive 1/3 the regular dose. The vaccine would be given twice with a three week gap.</li><li>Children who have significant declined immunity would be eligible for a booster shot after four weeks, said the report.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer-BioNTech's COVID Vaccine Gets Approval in South Korea for Kids 5-11 - Reuters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer-BioNTech's COVID Vaccine Gets Approval in South Korea for Kids 5-11 - Reuters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-23 17:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3803082-pfizer-biontechs-covid-vaccine-gets-approval-in-south-korea-for-kids-5-11-reuters><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>South Korea approved Pfizer (NYSE:PFE) BioNTech's (NASDAQ:BNTX) coronavirus vaccine for use in children ages five to 11 years, Reuters reported citing the Asian country's food and drug ministry.The ...</p>\n\n<a href=\"https://seekingalpha.com/news/3803082-pfizer-biontechs-covid-vaccine-gets-approval-in-south-korea-for-kids-5-11-reuters\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","PFE":"辉瑞","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓"},"source_url":"https://seekingalpha.com/news/3803082-pfizer-biontechs-covid-vaccine-gets-approval-in-south-korea-for-kids-5-11-reuters","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2213967923","content_text":"South Korea approved Pfizer (NYSE:PFE) BioNTech's (NASDAQ:BNTX) coronavirus vaccine for use in children ages five to 11 years, Reuters reported citing the Asian country's food and drug ministry.The kids will receive 1/3 the regular dose. The vaccine would be given twice with a three week gap.Children who have significant declined immunity would be eligible for a booster shot after four weeks, said the report.","news_type":1,"symbols_score_info":{"PFE":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":37,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2213967923","isCrawlerRequest":true}